How can organizations gain a complete picture of increasingly complex research fields and rapidly growing markets? The new Dimensions offering, Dimensions Biotech Solution, aims to enable companies to be one step ahead in the rapidly evolving domains of Life Sciences and Biotechnology.
We look at the omics and next-generation sequencing fields to illustrate the rapid evolution of research, generating substantial amounts of crucial data. However, this surge in data creation also introduces challenges such as data silos and inaccessibility.
Research on the fast-lane
“Omics” —the concise five-letter term— refers to a significant domain in life sciences. Omics sciences encompass fields of study in biological sciences that carry the suffix “-omics,” such as genomics, transcriptomics, proteomics, and metabolomics, and share the overarching aim of identifying, describing, and quantifying biomolecules and molecular processes that contribute to the form and function of cells and tissues.
A look at the growth projections for the omics market share aligns with the strong research focus on omics sciences. By 2025, the global single-cell multiomics market is anticipated to be US$5.32 billion, mainly driven by the increasing need for noninvasive diagnosis and personalized medicine (ref: Integrative Methods and Practical Challenges for Single-Cell Multi-omics). The global omics-based clinical trials market witnessed significant growth, valued at USD 26.2 billion in 2021, with an expected compound annual growth rate of 7.4% from 2022 to 2030. This surge has been possibly driven by the COVID-19 pandemic, increased investments in the pharmaceutical industry, growing demand for omics-based clinical trials, and the rising prevalence of chronic disorders (ref: Grand view research).
From tracking cancer cell evolution to deciphering Alzheimer’s hallmarks, researchers have been able to tap into omic sciences and advance our understanding of many areas in life sciences, including healthcare. The advancements from omics were put on a fast lane with the advent of technologies such as next-generation sequencing (NGS). NGS ushered in a new era in DNA and RNA sequencing, allowing for the rapid analysis of hundreds and thousands of genes or entire genomes.
This capacity for massive parallel sequencing in NGS has led to numerous studies and a plethora of data being produced in various -omics research domains. A quick full-text search in the Dimensions database for omics and NGS shows there were 9.5m publications, 2.5m patents, and even more with clinical trials, datasets, and funding.
Tackling the challenge of information silos
“Navigating intricate and rapidly burgeoning research fields and markets like NGS and omics poses a challenge in collating the essential information spread across different systems,” says Michael Torres, Sales Manager from Dimensions. “The first hurdle is accessing this extensive array of siloed data, followed by the substantial challenge of consolidating it into a unified, centralized repository. Another obstacle is extracting essential insights swiftly and efficiently, facilitating widespread sharing within the organization,” he explains.
In addition, to the complex research landscape with siloed information, the research publications stem from various sources, including Closed Publications, Open Publications, Patents, Clinical Trials, Funding Data, and Policy. “Despite the wealth of data available, most companies predominantly rely on open publications, which constitute less than 20% of the segregated information. Out of the Dimensions’ 141 million publications, only 48 million are openly accessible,” says Torres.
Enter Dimensions Biotech Solution
“We have spent a lot of time working closely with customers and performing in-depth needs assessments to understand how we can meet the complex challenges in the rapidly evolving domains within Life Sciences and Biotechnology, and that is how Dimensions Biotech Solution was born,” says Torres.
Dimensions Biotech Solution presents a centralized time-saving platform that merges 48 million open publications, 93 million closed publications, 158 million patents, 814 thousand clinical trials, and US$2.4 trillion in global funding data into visual and interactive applications for fast interpretation. This consolidated approach provides a comprehensive understanding of markets like NGS and omics.
Now, companies can adeptly navigate the life sciences and biotech market, facilitating market segmentation, audience identification and targeting, and strategic product positioning. It supports accurate market sizing, resource allocation, and cross-functional strategic alignment.
Torres adds, “This capability enhances cross-functional strategic alignment between product management, marketing, and sales, ensuring everyone has access to complete and relevant information.”
Moreover, the solution aids in identifying growth opportunities, monitoring market trends and competitive landscapes, and managing entire product lifecycles, from new introductions to updates, policy developments, improvements, and end-of-product lifecycle decisions.
The article has been prepared with inputs from Lauren Black, Product Specialist Manager at Dimensions, and Michael Torres, Sales Manager at Dimensions.